Tralokinumab Monotherapy in Adult Patients with Moderate-to-Severe Atopic Dermatitis: Regional Differences in Baseline Disease Characteristics and Prior Treatment in the ECZTRA 1 and ECZTRA 2 Trials

Main Article Content

Eric Simpson
Department of Dermatology, Oregon Health & Science University, Portland, OR, USA

Thomas Werfel
Department of Dermatology and Allergy, Hannover Medical School, Hannover, Germany

Thomas Bieber
Department of Dermatology and Allergy, University Medical Center, Bonn, Germany

Louise Steffensen
LEO Pharma A/S, Ballerup, Denmark

Alexandra Kuznetsova
LEO Pharma A/S, Ballerup, Denmark

Marie ?sterdal
LEO Pharma A/S, Ballerup, Denmark

Hidehisa Saeki
Department of Dermatology, Nippon Medical School, Tokyo, Japan

Keywords

Atopic Dermatitis, Tralokinumab, Monotherapy

Abstract

Abstract not available.

References

1. Barbarot S et al. Allergy 2018; 73: 1284−1293.

2. Nutten S. Ann Nutr Metab 2015; 66(Suppl 1): 8–16.

3. Weidinger S, Novak N. Lancet 2016; 387: 1109–1122.

4. Silverberg JI et al. Ann Allergy Asthma Immunol 2018; 121: 340–347.

5. Szegedi K et al. J Eur Acad Dermatol Venereol 2015; 29: 2136–2144.

6. Popovic B et al. J Mol Biol 2017; 429: 208–219.

7. Furue K et al. Immunology 2019; 158: 281–286.

8. Tsoi LC et al. J Invest Dermatol 2019; 139: 1480–1489.

9. Bieber T. Allergy 2020; 75: 54–62.

Article Sidebar

Poster PDF
Published
Oct 27, 2020
DOI https://doi.org/10.25251/skin.4.supp.101

Article Details

How to Cite
[1]
Simpson, E., Werfel, T., Bieber, T., Steffensen, L., Kuznetsova, A., ?sterdal, M. and Saeki, H. 2020. Tralokinumab Monotherapy in Adult Patients with Moderate-to-Severe Atopic Dermatitis: Regional Differences in Baseline Disease Characteristics and Prior Treatment in the ECZTRA 1 and ECZTRA 2 Trials. SKIN The Journal of Cutaneous Medicine. 4, 6 (Oct. 2020), s101. DOI:https://doi.org/10.25251/skin.4.supp.101.
Issue
Vol. 4 No. 6 (2020): November Issue & Poster Presentations (FC20 Dermatology Conference®)
Section
Atopic Dermatitis
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

All authors retain copyright in their articles. All articles published open access allowing for immediate free access to the work and permitting any user to read, download, copy, distribute, print, search, or link to the full texts of articles, crawl them for indexing, pass them as data to software or use them for any other lawful purpose. Permitted reuse is defined by  the following user license:
 

Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation. 

Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.ca/ojs/.

Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.

Most read articles by the same author(s)

1 2 3 4 5 > >>